The GH-IGF-SST system in hepatocellular carcinoma

Biological and molecular pathogenetic mechanisms and therapeutic targets

Claudia Pivonello, Maria Cristina De Martino, Mariarosaria Negri, Gaia Cuomo, Federica Cariati, Francesco Izzo, Annamaria Colao, Rosario Pivonello

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument. This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.

Original languageEnglish
Article number27
JournalInfectious Agents and Cancer
Volume9
Issue number1
DOIs
Publication statusPublished - Aug 20 2014

Fingerprint

Somatostatin
Hepatocellular Carcinoma
Somatostatin Receptors
Growth and Development
Therapeutics
Cell Proliferation
Neoplasms
Biliary Tract
Serum
Liver Diseases
Cell Differentiation
Hepatocytes
Apoptosis
Liver

Keywords

  • GH-IGF1 axis
  • Hepatocarcinogenesis
  • Hepatocarcinoma
  • Normal liver
  • Somatostatin
  • Somatostatin receptors

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

The GH-IGF-SST system in hepatocellular carcinoma : Biological and molecular pathogenetic mechanisms and therapeutic targets. / Pivonello, Claudia; De Martino, Maria Cristina; Negri, Mariarosaria; Cuomo, Gaia; Cariati, Federica; Izzo, Francesco; Colao, Annamaria; Pivonello, Rosario.

In: Infectious Agents and Cancer, Vol. 9, No. 1, 27, 20.08.2014.

Research output: Contribution to journalArticle

Pivonello, Claudia ; De Martino, Maria Cristina ; Negri, Mariarosaria ; Cuomo, Gaia ; Cariati, Federica ; Izzo, Francesco ; Colao, Annamaria ; Pivonello, Rosario. / The GH-IGF-SST system in hepatocellular carcinoma : Biological and molecular pathogenetic mechanisms and therapeutic targets. In: Infectious Agents and Cancer. 2014 ; Vol. 9, No. 1.
@article{bd8f5eceb7ef4bb486fbb35560cafb2c,
title = "The GH-IGF-SST system in hepatocellular carcinoma: Biological and molecular pathogenetic mechanisms and therapeutic targets",
abstract = "Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument. This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.",
keywords = "GH-IGF1 axis, Hepatocarcinogenesis, Hepatocarcinoma, Normal liver, Somatostatin, Somatostatin receptors",
author = "Claudia Pivonello and {De Martino}, {Maria Cristina} and Mariarosaria Negri and Gaia Cuomo and Federica Cariati and Francesco Izzo and Annamaria Colao and Rosario Pivonello",
year = "2014",
month = "8",
day = "20",
doi = "10.1186/1750-9378-9-27",
language = "English",
volume = "9",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The GH-IGF-SST system in hepatocellular carcinoma

T2 - Biological and molecular pathogenetic mechanisms and therapeutic targets

AU - Pivonello, Claudia

AU - De Martino, Maria Cristina

AU - Negri, Mariarosaria

AU - Cuomo, Gaia

AU - Cariati, Federica

AU - Izzo, Francesco

AU - Colao, Annamaria

AU - Pivonello, Rosario

PY - 2014/8/20

Y1 - 2014/8/20

N2 - Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument. This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.

AB - Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument. This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.

KW - GH-IGF1 axis

KW - Hepatocarcinogenesis

KW - Hepatocarcinoma

KW - Normal liver

KW - Somatostatin

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=84907911518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907911518&partnerID=8YFLogxK

U2 - 10.1186/1750-9378-9-27

DO - 10.1186/1750-9378-9-27

M3 - Article

VL - 9

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

IS - 1

M1 - 27

ER -